A Phase I/II, Double-blind, Randomized, Active-controlled, Age De-escalation Trial to Assess Safety and Immunogenicity of a Measles Rubella Vaccine (MRV) Microneedle Patch (MRV-MNP) in Adults, MRV-primed Toddlers, and MRV-naïve Infants
Latest Information Update: 07 May 2024
At a glance
- Drugs Measles and rubella vaccine microneedle patch Micron Biomedical (Primary) ; Measles and rubella virus vaccine
- Indications Measles; Rubella
- Focus Adverse reactions
- Sponsors Micron Biomedical
Most Recent Events
- 29 Apr 2024 Results assessing the tolerability, safety, and immunogenicity of an MRV-MNP in adults, MRV-vaccinated toddlers aged 15-18 months, and MRV-naive infants aged 9-10 months, published in the Lancet.
- 17 May 2023 According to Micron Biomedical media release,James Goodson is the co-investigator of the study.
- 17 May 2023 According to Micron Biomedical media release, data from this study were presented at the MICRONEEDLES 2023 conference.